GHRH analog is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-10-18. Numbers and descriptions here follow the published literature rather than marketing material.
Reverse-phase high-performance liquid chromatography is the standard tool for purity assessment. The technique separates the target peptide from truncated or modified byproducts. Mass spectrometry confirms molecular weight and supports sequence verification. Electrospray ionization and matrix-assisted laser desorption are both used. Amino acid analysis provides an independent check on composition. Purity values are commonly reported as area percentage from the chromatogram. Residual trifluoroacetate and water content are also measured in many quality programs.
Batch-to-batch consistency depends on solid-phase peptide synthesis and subsequent purification. Coupling efficiency, resin choice, and cleavage conditions all affect the final profile. Counter-ion content and moisture can shift the apparent mass of a batch. Documentation typically includes a certificate of analysis with chromatograms and spectra. Independent verification by a second laboratory is sometimes requested. Whether a given certificate reflects the actual vial contents depends on chain of custody. Analytical methods themselves carry uncertainty that should be stated alongside results.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
| Property | Value | Notes |
|---|---|---|
| Purity assessment | Reverse-phase HPLC | Reported as area percentage |
| Identity confirmation | Mass spectrometry | Electrospray or laser desorption |
| Powder storage | Minus 20 degrees Celsius or lower | Dark and dry conditions |
| Solution storage | Two to eight degrees Celsius | Avoid repeated freeze-thaw |
| Appearance | White to off-white powder | Common lyophilized form |
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
The chief characteristic of proteins that allows their diverse set of functions is their ability to bind other molecules specifically and tightly. The region of the protein responsible for binding another molecule is known as the binding site and is often a depression or "pocket" on the molecular surface. This binding ability is mediated by the tertiary structure of the protein, which defines the binding site pocket, and by the chemical properties of the surrounding amino acids' side chains. Protein binding can be extraordinarily tight and specific; for example, the ribonuclease inhibitor protein binds to human angiogenin with a sub-femtomolar dissociation constant (< 10−15 M) but does not bind at all to its amphibian homolog onconase (> 1 M). Extremely minor chemical changes such as the addition of a single methyl group to a binding partner can sometimes suffice to nearly eliminate binding; for example, the aminoacyl tRNA synthetase specific to the amino acid valine discriminates against the very similar side chain of the amino acid isoleucine. Proteins can bind to other proteins as well as to small-molecule substrates. When proteins bind specifically to other copies of the same molecule, they can oligomerize to form fibrils; this process occurs often in structural proteins that consist of globular monomers that self-associate to form rigid fibers.
== Ligands == The main ligand for α2β1 integrin is collagen, and thus, it is considered one of the main receptors for collagen on mammalian cells. The receptor interacts highly with fibrillar collagen types, especially type I collagen, which is plentiful in connective tissues including skin, tendon, and bone. It also recognizes type IV collagen, which is an important part of basement membranes and permits cells to associate with different ECM components. Even though collagen is its primary ligand, there are several other proteins with which α2β1 integrin interacts, such as Laminin; however, the affinity in these cases is usually lower. The ligand binding occurs due to the presence of the inserted αI (I) domain that is located in the extracellular domain of the α2 subunit. The MIDAS domain of the protein binds divalent cation, magnesium ions (Mg²⁺) and manganese ions (Mn²⁺), required for the ligand binding. Changes in conformation control the binding affinity of the receptor towards the extracellular ligands and help α2β1 integrin to change from an inactive to an active state under the influence of both extracellular and intracellular stimuli. The interaction between α2β1 integrin and collagen anchors cells to the extracellular matrix and initiates intracellular signaling pathways that regulate cellular behavior.
Several medications can help alleviate symptoms of EDS, such as pain and blood pressure drugs, which reduce joint pain and complications caused by blood vessel weakness. Some forms of EDS result in a normal life expectancy, but those that affect blood vessels generally decrease it. All forms of EDS can result in fatal outcomes for some patients. While EDS affects at least one in 5,000 people globally, other types occur at lower frequencies. The prognosis depends on the specific disorder. Excess mobility was first described by Hippocrates in 400 BC. The syndromes are named after two physicians, Edvard Ehlers and Henri-Alexandre Danlos, who described them at the turn of the 20th century.
Sources: en.wikipedia.org
==== Medical and higher education ==== Martin Luther King Jr./Drew Medical Center in Los Angeles (now Martin Luther King Jr. Outpatient Center) Charles R. Drew University of Medicine and Science in California Charles Drew Health Center in Omaha, Nebraska Charles Drew Science Scholars at Michigan State University Drew Health Foundation in East Palo Alto, California Charles Drew Community Health Center in Burlington, North Carolina Charles Drew Pre-Health Society at the University of Rochester Drew Wellness Center in Columbia, South Carolina Dr. Charles Drew Red Cross Blood and Platelet Donation Center in Washington, D.C. Charles R. Drew Hall at Howard University Charles Drew Memorial Cultural House at Amherst College Charles Drew Premedical Society at Columbia University
== Hydrogen bonds between subunits == Hydrogen bonding networks between subunits has been shown to be important for the stability of the tetrameric quaternary protein structure. For example, a study of SDH which used diverse methods such as protein sequence alignments, structural comparisons, energy calculations, gel filtration experiments and enzyme kinetics experiments, could reveal an important hydrogen bonding network which stabilizes the tetrameric quaternary structure in mammalian SDH.
In October 2021, Carina Palacios Quincho assumed office as Peruvian ambassador to Bolivia. However, a scandal erupted regarding her appointment because Palacios was a founder of Perú Libre and a former official of the Junín regional government during the administration of Vladimir Cerrón, leader of that political organization. In addition, it was revealed that Palacios had issued documents signing herself as an engineer despite not holding such a degree at the time. During that month, Castillo met with Luis Arce, president of Bolivia, within the framework of the Peru-Bolivia Binational Cabinet. In 2018, Castillo expressed his support for Bolivia obtaining access to the sea, an act that was recorded in a video. This sparked a scandal when the audiovisual material was revealed, prompting journalist Fernando del Rincón in January 2022 to ask Castillo about that possibility. Castillo stated that on that occasion he had not made those remarks as president but that "now we will consult the people. For that, the people need to express themselves. If Peru agrees, I owe myself to the people; I would never do things that the people do not want". Subsequently, Castillo apologized for what he had said. The foreign ministry, for its part, denied that the government promoted a cession of Peruvian territory to the highland country so that it could obtain access to the sea.
== Early life and education == Philip E. Dawson obtained his bachelor's degree in chemistry from Washington University in St. Louis, graduating magna cum laude. He went on to earn his Ph.D. in chemistry from Scripps Research in 1996. Following his doctoral studies, Dawson conducted postdoctoral research at the California Institute of Technology before returning to Scripps Research as an assistant professor.
Sources: en.wikipedia.org
The powder is normally held at minus twenty degrees Celsius or below. Light and moisture exposure should be minimized. Repeated warming and cooling cycles are avoided.
Reverse-phase high-performance liquid chromatography is used for purity. Mass spectrometry confirms molecular weight and sequence integrity. Amino acid analysis offers an additional compositional check.
Published stability data for dissolved material are limited and vary with conditions. Refrigerated solutions are generally used within a short period. The exact shelf life depends on concentration, buffer, and handling.
No. It is a laboratory-made analog of growth hormone-releasing hormone. The natural hormone is a 44-residue peptide, while the analog is built on a shorter 29-residue fragment.